Tempus Ai Stock Earnings Reports

Tempus reported a strong Q1 2026: revenue of $348.1M, up ~36% year-over-year, driven by Diagnostics ($261.1M, ~35% growth) and Data & Applications ($87M, 40.5% growth). Oncology therapy-selection (solid tumor, liquid biopsy, MRD) was a major driver; hereditary slowed as expected but is expected to return to mid-teens growth in H2. The Data & Apps business continues to scale with multiple large, multi-year strategic collaborations (notably Merck and an expanded Gilead relationship), growing TCV, and a >500 petabyte de-identified dataset that is being used for model-building. Management raised full-year revenue guidance to $1.59B–$1.60B and expects adjusted EBITDA of about $65M for 2026. MRD is growing fast but is being rolled out carefully in coordination with partners due to reimbursement dynamics; management sees significant upside if reimbursement improves. FDA interactions: one approved assay is being expanded, other submissions (liquid biopsy, RNA) are in process; no new update on the xF submission. Cash flow was negative in Q1 due to timing (payables, bonuses, deferred revenue dynamics), but management expects a meaningful improvement in Q2 and continued improvement as adjusted EBITDA grows. Attach rates for Tempus algorithms on solid tumor assays (~40%) and a suite of analytics capabilities are driving differentiated growth and physician adoption. Overall, management characterizes the business as durable, diversified, and positioned for continued multi-year growth with improving operating leverage.